Sadik, A. A. S., Dardani, C., Pagoni, P., Havdahl, K. A., Stergiakouli, E., Grove, J., Khandaker, G. M., Sullivan, S. A., Zammit, S., Jones, H. J., Davey Smith, G., Dalman, C., Karlsson, H., Gardner, R. M., & Rai, D. (2022). Parental inflammatory bowel disease and autism in children: Triangulating the evidence using four complementary study designs. *Nature Medicine, 28*(7), 1406-1411. Advance online publication. https://doi.org/10.1038/s41591-022-01845-9

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1038/s41591-022-01845-9

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Nature at https://doi.org/10.1038/s41591-022-01845-9. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Parental inflammatory bowel disease and autism in children

Evidence linking parental inflammatory bowel disease (IBD) with autism in children is inconclusive. We conducted four complementary studies to investigate associations between parental IBD and autism in children, and elucidated their underlying etiology. Conducting a nationwide population-based cohort study using Swedish registers, we found evidence of associations between parental diagnoses of IBD and autism in children. Polygenic risk score analyses of the Avon Longitudinal Study of Parents and Children suggested associations between maternal genetic liability to IBD and autistic traits in children. Two-sample Mendelian randomization analyses provided evidence of a potential causal effect of genetic liability to IBD, especially ulcerative colitis, on autism. Linkage disequilibrium score regression did not indicate a genetic correlation between IBD and autism. Triangulating evidence from these four complementary approaches, we found evidence of a potential causal link between parental, particularly maternal, IBD and autism in children. Perinatal immune dysregulation, micronutrient malabsorption and anemia may be implicated.
Using logistic regression, we assessed the associations between parental IBD diagnoses and autism in children. We ran crude models (Model 1), as well as models adjusted for covariates that have been previously identified as associated with autism in the Swedish registers, including parental age at delivery, migrant status, education level, family income quintile at birth, parents’ history of psychiatric diagnosis prior to the birth of the child, and child’s sex, birth year, and birth order (Model 2). In order to avoid potential bias from assortative mating in Model 2, we additionally mutually adjusted for maternal and paternal IBD diagnoses (Model 3). Maternal IBD diagnosis was associated with autism in children in crude and adjusted models.

**Table 1** Summary of the research question, data sources used, as well as key strengths and limitations of each methodological approach applied in the present study

| Method | Research question | Data sources | Key strengths | Key limitations |
|--------|-------------------|--------------|---------------|----------------|
| Nationwide registry-based cohort study in Sweden | Are parental diagnoses of IBD associated with autism in the children? | Medical and administrative registers | Large, diverse total population, intergenerational sample; prospective recording of data; low rate of loss to follow up; large availability of confounder data | Unmeasured confounding; exposure misclassification |
| Linkage Disequilibrium score regression | Is there a shared genetic background between IBD and autism? | GWAS summary data | Use of GWAS summary data instead of twin data or individual-level data maximizes sample sizes and power; indicates genetic correlation due to linkage disequilibrium or pleiotropy | Cannot assess causality |
| PRS analysis in the ALSPAC cohort | Is maternal genetic liability for IBD associated with childhood broad autism phenotype? | GWAS summary data and individual-level genotype and phenotype data | Estimates the underlying genetic liability for IBD, regardless of diagnosis; allows the refinement of the exposure used in the context of an observational study (potentially overcoming exposure misclassification of an observational study); can indicate potentially genetically transmitted versus in-utero effects through the assessment of the maternal versus child’s underlying genetic liability for IBD; large birth cohort; prospectively collected information on the outcome phenotype | Cannot decipher whether the identified associations are causal or instead owing to pleiotropy; polygenic risk scores at lower \( P \)-value thresholds might not adequately capture the exposure phenotype; attrition can influence association estimates |
| Two-sample MR | Does genetic liability to IBD have a causal effect on autism? | GWAS summary data, exposure proxied by variants robustly associated with the exposure | Using common genetic variants as instruments for IBD allows the assessment of reverse causation; allows the assessment of the influence of pleiotropy | Cannot decipher whether the identified causal effect is of parental origin; can be biased by dynastic effects and assortative mating |

Data (Fig. 3, Supplementary Tables S1 and S2). Using logistic regression, we assessed the associations between parental IBD diagnoses and autism in children. We ran crude models (Model 1), as well as models adjusted for covariates that have been previously identified as associated with autism in the Swedish registers, including parental age at delivery, migrant status, education level, family income quintile at birth, parents’ history of psychiatric diagnosis prior to the birth of the child, and child’s sex, birth year, and birth order (Model 2). In order to avoid potential bias from assortative mating in Model 2, we additionally mutually adjusted for maternal and paternal IBD diagnoses (Model 3). Maternal IBD diagnosis was associated with autism in children in crude and adjusted models.
(any IBD diagnosis: odds ratio (OR)$_{\text{MODEL1}}$ = 1.32; 95% confidence intervals (CIs): 1.25 to 1.40; Table 2). Similar results were observed in analyses of maternal UC and Crohn’s diagnoses and autism in children (Table 2). The maternal IBD associations with autism were weaker (OR$_{\text{MODEL1}}$ = 1.09; 95% CIs 1.02 to 1.17) than the maternal associations (Table 2). Results of the analysis were not sensitive to the choice of parental psychiatric history variable (broad psychiatric history versus parental diagnoses of autism specifically) or exclusion procedures that aimed to control for neurodevelopmental outcomes that we assumed to have a genetic cause, though point estimates were lower in analyses restricted to parental UC diagnoses and autism in children (Table 2). The paternal IBD associations with autism were weaker (OR$_{\text{MODEL1}}$ = 1.12) compared with those of UC and Crohn’s, although CIs overlapped (Supplementary Table S3).

Point estimates for associations of parental IBD diagnoses to autism without intellectual disabilities (IDs) were higher than those for children with IDs (Supplementary Table S4). The total numbers for those exposed to maternal or paternal Crohn’s, UC, or other IBD do not sum to the total exposed to any IBD because some mothers or fathers received both a Crohn’s and a UC diagnosis. Supplementary Fig. S2 shows details on the prevalence and overlap in diagnoses in the study sample. Crude models. Models adjusted for child’s sex, year of birth, birth order, maternal/paternal age, migrant status, education level, family income, and parental psychiatric history. Mutually adjusted models for maternal/paternal IBD diagnoses, child’s sex, year of birth, birth order, maternal/paternal age, migrant status, education level, family income, and parental psychiatric history. *P value is less than Bonferroni-corrected value of 0.0001, accounting for 42 models in Study 1. Supplementary Table 19 shows exact P values. Excluding 2,144 children without IBD: OR (95% CIs): (0.99, 1.02) and assessed associations with an available measure of broad autistic traits, autism mean factor score29.

### Table 2 | Associations between maternal or paternal diagnosis for any IBD, UC, Crohn’s, or other IBD, and diagnosis of autism in children

| Exposure | n ASD/N total (% ASD)* | Model1 OR (95% CIs) | Model2 OR (95% CIs) | Model3 OR (95% CIs) |
|----------|------------------------|----------------------|----------------------|----------------------|
| No maternal IBD | 43,568/2,272,606 (1.92%) | Ref | Ref | Ref |
| Any maternal IBD | 1,361/51,621 (2.64%) | 1.39 (1.31,1.47) | <0.001* | 1.32 (1.24,1.40) | <0.001* | 1.32 (1.25,1.40) | <0.001* |
| Maternal Crohn’s | 422/17,832 (2.37%) | 1.23 (1.09,1.40) | 0.001* | 1.19 (1.05,1.35) | 0.006 | 1.20 (1.06,1.36) | 0.004 |
| Maternal UC | 292/12,390 (2.36%) | 1.24 (1.12,1.38) | <0.001* | 1.22 (1.10,1.35) | <0.001* | 1.22 (1.10,1.36) | 0.001 |
| Maternal Other IBD | 722/24,865 (2.90%) | 1.53 (1.42,1.66) | <0.001* | 1.42 (1.32,1.54) | <0.001* | 1.43 (1.32,1.55) | <0.001* |
| Maternal Crohn’s or UC | 639/26,756 (2.39%) | 1.25 (1.15,1.35) | <0.001* | 1.21 (1.11,1.32) | <0.001* | 1.22 (1.12,1.32) | <0.001* |
| No paternal IBD | 43,989/2,281,119 (1.93%) | Ref | Ref | Ref |
| Any paternal IBD | 940/43,108 (2.18%) | 1.14 (1.06,1.22) | <0.001* | 1.11 (1.03,1.18) | 0.004 | 1.09 (1.02,1.17) | 0.012 |
| Paternal Crohn’s | 346/18,290 (1.89%) | 1.18 (1.04,1.35) | 0.013 | 1.16 (1.02,1.33) | 0.023 | 1.16 (1.01,1.32) | 0.031 |
| Paternal UC | 254/11,274 (2.25%) | 0.99 (0.88,1.10) | 0.806 | 0.98 (0.87,1.09) | 0.662 | 0.97 (0.86,1.08) | 0.575 |
| Paternal other IBD | 407/16,958 (2.40%) | 1.25 (1.12,1.38) | <0.001* | 1.19 (1.07,1.32) | 0.001* | 1.17 (1.05,1.30) | 0.003 |
| Paternal Crohn’s or UC | 533/26,150 (2.04%) | 1.06 (0.97,1.16) | 0.187 | 1.05 (0.96,1.15) | 0.312 | 1.04 (0.95,1.14) | 0.408 |

*The total numbers for those exposed to maternal or paternal Crohn’s, UC, or other IBD do not sum to the total exposed to any IBD because some mothers or fathers received both a Crohn’s and a UC diagnosis. Supplementary Fig. S2 shows details on the prevalence and overlap in diagnoses in the study sample. Crude models. Models adjusted for child’s sex, year of birth, birth order, maternal/paternal age, migrant status, education level, family income, and parental psychiatric history. Mutually adjusted models for maternal/paternal IBD diagnoses, child’s sex, year of birth, birth order, maternal/paternal age, migrant status, education level, family income, and parental psychiatric history. *P value is less than Bonferroni-corrected value of 0.0001, accounting for 42 models in Study 1. Supplementary Table 19 shows exact P values. Excluding 2,144 children without IBD: OR (95% CIs): (0.99, 1.02) and assessed associations with an available measure of broad autistic traits, autism mean factor score29.

### Table 3 | Genetic correlation (r_g) between liability to autism and IBD, UC, and Crohn’s

| Trait 1 | Trait 2 | r_g (95% CIs) | P |
|---------|---------|---------------|---|
| Autism | IBD | −0.0615 (−0.15, 0.02) | 0.158 |
| Autism | UC | −0.0656 (−0.17, 0.04) | 0.2064 |
| Autism | Crohn’s | −0.0403 (−0.13, 0.05) | 0.3551 |

Genetic correlation coefficients (r_g), 95% CIs and P values calculated by LDSC. There were no multiple-test corrections made.

### Study 2: Genetic correlation between IBD and autism. Linkage disequilibrium score regression (LDSC) allows the estimation of the genetic correlation between complex traits such as IBD and autism by utilizing GWAS summary data.20,21 (Table 1).

Using the latest GWAS summary statistics on IBD (N = 25,042; N controls = 34,915) (ref. 21), Crohn’s (N = 12,194; N controls = 28,072) (ref. 20), UC (N = 12,366; N controls = 16,013) (ref. 21), and autism (N = 18,381; N controls = 28,911) (ref. 20), we performed LDSC. We found no evidence of a genetic correlation between genetic liability to autism and IBD, UC, or Crohn’s (Table 3). Heritability scores (z scores: 8.34–11.75), chi-squares (1.20–1.53), and intercepts (1.01–1.12) satisfied the conditions to provide reliable LDSC estimates (Supplementary Table S5).

### Study 3: Polygenic risk for IBD and broad autistic traits. Polygenic Risk Score (PRS) approaches enable the estimation of an individual’s underlying genetic liability to a complex trait. PRSs require individual-level genotype data, and are calculated as the sum of the individual’s risk alleles, weighted by the effect sizes of each variant identified in the GWAS of the trait.24. In the context of the present study, individual-level data from the Avon Longitudinal Study of Parents and Children (ALSPAC) were used.25-27. PRS approaches are particularly important for the triangulation of evidence from traditional observational approaches, since they allow the refinement of the exposure used in the context of the observational study (that is, they can potentially overcome misclassification bias of an observational study (Table 1)).

In 7,348 mothers and 7,503 children of the ALSPAC cohort, we calculated PRSs for IBD, Crohn’s, and UC, using the latest available GWAS summary data, and assessed associations with an available measure of broad autistic traits, autism mean factor score (Methods, Extended Data Fig. 4).

**Maternal PRS for IBD and broad autistic traits in children.** Maternal polygenic risk for UC and Crohn’s was associated with a higher autism factor mean score in the child (UC: βPRS = 0.02; 95% CIs: 0.003 to 0.05; P = 0.03; Crohn’s: βPRS = 0.03; 95% CIs: 0.01 to 0.05; P = 0.004). Similar results were found across other P-value thresholds (0.50–0.05). The effect size of the association between maternal polygenic risk for IBD and autism factor mean score, was comparable with that of UC and Crohn’s, although CIs crossed the null
We used four complementary approaches to investigate the associations between parental diagnoses and genetic liability to IBD and autism in children. On conducting a nationwide register-based cohort study in Sweden we found evidence of associations between parental diagnoses of IBD and autism in children. Importantly, the maternal effect sizes were larger than the paternal sizes, without overlapping CIs. PRS analyses in the ALSPAC birth cohort suggested associations between maternal genetic liability to IBD and autism traits in children, while two-sample MR studies provided evidence of a potential causal effect of genetic liability to IBD on autism risk. There was no evidence to suggest a genetic correlation between autism and IBD, as indicated by LDSC analyses.

A number of studies have investigated the potential associations between parental autoimmune conditions and autism. Several parental autoimmune conditions have been previously identified as linked to autism in children, including rheumatoid arthritis and psoriasis. In the case of IBD, evidence from previous studies is inconclusive. In contrast to studies to date, the use of four distinct study designs is a notable strength of our approach. Using study designs with different strengths and sources of bias (Table 1) allowed the triangulation of our findings, rather than relying on arbitrary P-value thresholds. The Swedish nationwide register-based cohort study of over two million parent–child pairs is the largest to date on parental IBD and autism in children. In addition, the present study benefited from the longest to date follow-up period (1987–2016), as well as exposure and outcome ascertainment from both inpatient and outpatient specialist care.

The ALSPAC cohort containing genotype data for over 7,000 mothers and children, as well as broad autistic trait measures for over 13,000 children, is one of the richest resources for the investigation of the potential polygenic associations between maternal

### Table 4 | Associations between maternal and child PRS for IBD, UC, Crohn’s at P-value threshold 0.05, and standardized autism factor mean score in the children of the ALSPAC birth cohort

| Exposure                        | β (95% CIs)          | P  |
|---------------------------------|----------------------|----|
| Maternal IBD PRS                | 0.02 (−0.004, 0.004) | 0.1|
| Maternal UC PRS                 | 0.02 (0.003, 0.005)  | 0.03|
| Maternal Crohn’s PRS            | 0.03 (0.01, 0.05)    | 0.004|
| Child’s IBD PRS                 | 0.003 (−0.02, 0.02)  | 0.79|
| Child’s UC PRS                  | 0.001 (−0.02, 0.02)  | 0.89|
| Child’s Crohn’s PRS             | 0.007 (−0.01, 0.03)  | 0.49|

N = 7,348 mother-child pairs for analyses involving mothers’ PRSs. N = 7,503 children for analyses involving children’s PRS. Beta coefficients, 95% CIs, and P values calculated by linear regression of the PRS for IBD, UC, or Crohn’s on the standardized autism factor mean score in the children, adjusted for child’s sex and the first ten principal components of the ALSPAC genotype data.

### Table 5 | Mendelian randomization IVW estimates for the effect of genetic liability to IBD, Crohn’s, and UC on autism and vice versa

| Exposure                        | Outcome          | OR (95% CIs)       | P   |
|---------------------------------|------------------|--------------------|----|
| Genetic liability to IBD        | Autism           | 1.02 (1.0, 1.05)   | 0.1 |
| Genetic liability to UC         | Autism           | 1.04 (1.01, 1.07)  | 0.006|
| Genetic liability to Crohn’s    | Autism           | 1.01 (1.0, 1.04)   | 0.2 |
| Genetic liability to UC         | Crohn’s          | 0.90 (0.73, 1.11)  | 0.32|
| Genetic liability to autism     | UC               | 0.95 (0.77, 1.18)  | 0.65|
| Genetic liability to autism     | Crohn’s          | 0.85 (0.63, 1.15)  | 0.29|

ORs, 95% CIs, and P values calculated by inverse variance-weighted (IVW) Mendelian randomization. There were no multiple-test corrections made.

### Discussion

Causal effects of genetic liability to autism on risk of IBD. We assessed the possibility of reverse causation by performing bidirectional two-sample MR. We extracted common genetic variants associated (P ≤ 5 × 10^{-8}) with autism, as well as autism without ID, and assessed their potential causal effects on IBD (N_cases = 25,042; N_controls = 34,915), UC (N_cases = 12,366; N_controls = 33,609), and Crohn’s (N_cases = 12,194; N_controls = 28,072) (ref. 23) (Online Methods, Extended Data Figs. 6 and 7, Supplementary Tables S8 and S9). The mean F statistic of the autism instruments was 28, suggesting adequate strength. There was no evidence of a causal effect of genetic liability to autism on risk of IBD, UC, or Crohn’s (Table 5). The estimates were consistent across sensitivity analyses, with overlapping confidence intervals, and were unlikely to be influenced by horizontal pleiotropy (Supplementary Table S12). Repeating our analyses with instruments extracted from the autism GWAS excluding all ID cases yielded similar results (Supplementary Table S13).
polygenic risk for IBD and autism in children. Finally, in the MR analyses, we used the largest GWAS data available for all conditions and conducted several sensitivity analyses to test the robustness of our findings.

Considering study limitations in the Swedish registers, the possibility of measurement error in IBD diagnoses cannot be excluded. However, this is likely to be nondifferential in relation to our study outcome and would therefore bias our findings towards the null. Second, while PRSs were based on large GWAS samples, it was not possible for us to investigate the variance explained by the PRSs in our target sample. However, based on previous studies\cite{44,45}, it could be expected that our PRSs potentially explain little variance in the phenotype (\(\approx 1.5\text{–}3.0\%\)), a limitation that could be overcome with future larger GWAS. Third, the autism mean factor score used in the present analyses was derived from individual measures that were not primarily intended to assess autism. However, the score has been found predictive of a clinical autism diagnosis (measured independent of the variables contributing to the derivation of the mean factor score) and presents associations with autism PRS in ALSPAC, as suggested by previous studies\cite{46,47}. Fourth, in two-sample MR analyses investigating the effects of genetic liability to autism on risk of IBD, we used a relaxed instrument inclusion \(p\)-value threshold, this could potentially result in including weak instruments and therefore bias the causal effect estimates. The \(F\) statistic of the autism instruments in our analyses suggested that weak instrument bias is unlikely. Fifth, although we performed a series of sensitivity analyses to assess the robustness of the causal effect estimates, the possibility of horizontal pleiotropy influencing the present findings cannot entirely be ruled out, especially considering emerging evidence on the genetic architecture of IBD, implicating immune and endocrine-related genes\cite{48}. Sixth, using GWAS data, we could only investigate the possible contribution of common variants acting under an additive model and not any contribution from rare variation which is found to be implicated in autism\cite{49,50}. Finally, an important consideration is that the present study has been conducted using samples and GWAS data of predominantly European ancestry individuals. Although a proportion of index children in the registry-based study had at least one parent of non-European descent (10\%), the use of European ancestry summary and individual-level genetic data in LDSC, PRS, and MR analyses, was unavoidable considering the largest available GWAS on autism and IBD has been conducted in European ancestry samples. The increasing representation of ancestrally diverse populations in biobanks and health registers will allow future studies to build on the present findings.

Overall, our findings suggest larger maternal effect sizes than paternal in the registry-based study, in combination with the identified associations between maternal, but not child’s, PRS for IBD and child’s autism factor mean score, which could potentially indicate in-utero effects. This could be further supported considering we did not find evidence of a genetic correlation between autism and IBD. Specifically, based on liability-threshold models of inheritance\cite{51,52,53} (and assuming that liability to IBD is normally distributed in the population), it could be hypothesized that liability to IBD will be expressed after a threshold has been exceeded, depending on a synergy of genetic variation, environmental factors, and chance. Mothers close to the threshold, but not exceeding it, could be expected to express subphenotypic manifestations of IBD, such as immunological alterations, micronutrient deficiencies, or anemia. These subphenotypic manifestations could influence fetal development. In fact, several immune pathways have been implicated in both Crohn’s and UC (which are strongly genetically correlated: \(r = 0.5\); \(P = 2.0 \times 10^{-11}\) (ref. \cite{54})), including T-helper 1, T-helper 2, and T-helper 17 cytokines\cite{55}, which are increasingly identified as linked to perinatal complications\cite{56,57}, as well as autism\cite{58,59}. Similarly, micronutrient malabsorption and anemia during pregnancy have been found to be associated with autism in children\cite{60,61}. The availability of genotype and biospecimen data in autism family cohorts such as the Simons Simplex Collection and the Simons Foundation Powering Autism Research (SPARK)\cite{55,56} is expected to allow the integration of genomic, immune, and gut microbiome profiling approaches to elucidate the potential etiology and biological pathways underlying the identified associations.

In conclusion, triangulating evidence from a nationwide register-based cohort study, genetic correlation, PRS analyses, and MR, we found evidence suggesting associations between parental, particularly maternal, diagnoses of IBD, and autism in children. Links between maternal genetic liability to IBD and autism in children may reflect the influence of the maternal genotype on the prenatal/intrauterine environment. Investigating the mechanisms behind these findings may provide valuable insights into the origins of autism.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41591-022-01845-9.

Received: 6 June 2021; Accepted: 28 April 2022; Published online: 02 June 2022

References
1. Mubashir, S., Farrugia, M., Coretti, L., Pessia, M. & D’Adamo, M. C. Autism spectrum disorder. *Malta Med. J.* 32, 56–66 (2020).
2. Holingue, C., Newill, C., Lee, L. C., Pasricha, P. J. & Daniele Fallin, M. Gastrointestinal symptoms in autism spectrum disorder: a review of the literature on ascertainment and prevalence. *Autism Res.* 11, 24–36 (2018).
3. Lee, M. et al. Association of autism spectrum disorders and inflammatory bowel disease. *J. Autism Dev. Disord.* 48, 1523–1529 (2018).
4. Graham, D. B. & Xavier, R. J. Pathway paradigms revealed from the genetics of inflammatory bowel disease. *Nature* 578, 527–539 (2020).
5. Yoon, S. M. Micronutrient deficiencies in inflammatory bowel disease: trivial or crucial? *Intest. Res.* 14, 109–110 (2016).
6. Weisshof, R. & Chermesh, I. Micronutrient deficiencies in inflammatory bowel disease. *Curr. Opin. Clin. Nutr. Metab. Care* 18, 576–581 (2015).
7. Osokine, I. & Erlebacher, A. Inflammation and autism: from maternal gut to fetal brain. *Trends Mol. Med.* 23, 1070–1071 (2017).
8. Devilliers, E. A. et al. Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study. *Br. Med. J.* 359, 1–9 (2017).
9. Tan, M. et al. Maternal folic acid and micronutrient supplementation is associated with vitamin levels and symptoms in children with autism spectrum disorders. *Reprod. Toxicol.* 91, 109–115 (2020).
10. Wiegensma, A. M., Dalman, C., Lee, B. K., Karlsson, H. & Gardner, R. M. Association of prenatal maternal anemia with neurodevelopmental disorders. *JAMA Psychiatry* 76, 1294–1304 (2019).
11. Keil, A. et al. Parental autoimmune diseases associated with autism spectrum disorders in offspring. *Epidemiology* 21, 805–808 (2010).
12. Allädhött, H. O. et al. Association of family history of autoimmune diseases and autism spectrum disorders. *Pediatrics* 124, 687–694 (2009).
13. Andersen, A. B. T., Ehrenstein, V., Erichsen, R., Froslev, T. & Sørensen, H. T. Autism spectrum disorders in parents of children with inflammatory bowel disease—a nationwide cohort study in Denmark. *Clin. and Exp. Gastroenterol.* 7, 105–110 (2014).
14. Moursidsen, S. E., Rich, B., Isager, T. & Nedergaard, N. J. Autoimmune diseases in parents of children with infantile autism: A case-control study. *Dev. Med. Child Neuro* 49, 429–432 (2007).
15. Idring, S. et al. Parental age and the risk of autism spectrum disorders: findings from a Swedish population-based cohort. *Int. J. Epidemiol.* 43, 107–115 (2014).
16. Magnusson, C. et al. Migration and autism spectrum disorder: population-based study. *Br. J. Psychiatry* 201, 109–115 (2012).
17. Rai, D. et al. Parental socioeconomic status and risk of offspring autism spectrum disorders in a Swedish population-based study. *J. Am. Acad. Child Adolesc. Psychiatry* 51, 467–476 (2012).
18. Xie, S. et al. The familial risk of autism spectrum disorder with and without intellectual disability. *Autism Res.* 13, 2242–2250 (2020).
The iPSYCH Autism Spectrum Disorder Working Group

Jakob Grove

The iPSYCH Autism Spectrum Disorder Working Group

19. Madley-Dowd, P., Rai, D., Zammit, S. & Heron, J. Simulations and directed
acyclic graphs explained why assortative mating biases the prenatal negative
control design. J. Clin. Epidemiol. 118, 9–17 (2020).

20. Bulik-Sullivan, B. K. et al. LD score regression distinguishes confounding
from polygenicity in genome-wide association studies. Nat. Genet. 47,
291–295 (2015).

21. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases
and traits. Nat. Genet. 47, 1236–1241 (2015).

22. De Lange, K. M. et al. Genome-wide association study implicates immune
activation of multiple integrin genes in inflammatory bowel disease. Nat.
Genet. 49, 256–261 (2017).

23. Grove, J. et al. Identification of common genetic risk variants for autism
spectrum disorder HHS Public Access Author manuscript. Nat. Genet.
51, 431–444 (2019).

24. Choi, S. W., Mak, T. S. H. & O’Reilly, P. F. Tutorial: a guide to performing
polygenic risk score analyses. Nat. Protoc. 15, 2759–2772 (2020).

25. Fraser, A. et al. Cohort profile: the Avon Longitudinal Study of Parents and
Children: ALSPAC cohorts mother. Int. J. Epidemiol. 42, 97–110 (2013).

26. Boyd, A. et al. Cohort profile: The Children of the 90’s–The index offspring
of the Avon Longitudinal Study of Parents and Children. Int. J. Epidemiol.
42, 111–127 (2013).

27. Northstone, K. et al. The Avon Longitudinal Study of Parents and Children
(ALSPAC): an update on the enrolled sample of index children in 2019
(version 1; peer review: 2 approved). Welcome Open Res. 4, 1–10 (2019).

28. Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological
epidemiology. Int. J. Epidemiol. 45, 1866–1886 (2016).

29. Steer, C. D., Golding, J. & Bolton, P. F. Traits contributing to the autistic
spectrum. PLoS One 5, e12633 (2010).

30. Sanderson, E. et al. Mendelian randomization. Nat. Rev. Methods Prim.
2, 6 (2022).

31. Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for
causal inference in epidemiological studies. Hum. Mol. Genet. 23, R89–R98
(2014).

32. Davey Smith, G. & Ebrahim, S. ‘Mendelian randomisation’: can genetic
epidemiology contribute to understanding environmental determinants of
disease? Int. J. Epidemiol. 32, 1–22 (2003).

33. Davey Smith, G. & Hemani, G. Mendelian randomization: Genetic anchors for
causal inference in epidemiological studies. Hum. Mol. Genet. 23,
R89–R98 (2014).

34. Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization
studies: subsample and 2-sample instrumental variable estimators. Am. J.
Epidemiol. 178, 1177–1184 (2013).

35. Rom, A. L. et al. Parental rheumatoid arthritis and autism spectrum disorders
in offspring: a Danish nationwide cohort study. J. Am. Acad. Child Adolesc.
Psychiatry 57, 28–32.e1 (2018).

36. Croen, L. A., Grether, J. K., Yoshida, C. K., Oodoli, R. & De Water, J. Van
Maternal autoimmune diseases, asthma and allergies, and childhood autism
spectrum disorders: a case-control study. Arch. Pediatr. Adolesc. Med.
159, 151–157 (2005).

37. Sterne, J. A. C., Davey Smith, G. & Cox, D. R. Sifting the evidence—what’s
wrong with significance tests? Brit. Med. J. 332, 226 (2001).

38. Glashan, K. P., Coleman, J. R. L., O’Reilly, P. F., Galloway, J. & Lewis, C. M.
Investigating pleiotropy between depression and autoimmune diseases using
the UK Biobank. BP-GPS 1, 48–58 (2021).

39. Chen, G. B. et al. Performance of risk prediction for inflammatory bowel
disease based on genotyping platform and genomic risk score method. BMC
Med. Genet. 18, 94 (2017).

40. Rai, D. et al. Association of autistic traits with depression from childhood to
age 18 years. JAMA Psychiatry 75, 835–843 (2018).

41. Lasconi, C. et al. Variant-to-gene-mapping analyses reveal a role for the
hypothalamus in genetic susceptibility to inflammatory bowel disease. CMGH
11, 667–682 (2021).

42. Buxbaum, J. D. Multiple rare variants in the etiology of autism spectrum
disorders. Dialogues Clin. Neurosci. 11, 35–43 (2009).

43. Balzola, F., Bernstein, C., Ho, G. T. & Russell, K. K. Deep resequencing of
GWAS loci identifies independent rare variants associated with inflammatory
bowel disease: commentary. Inflamm. Bowel Dis. Monit. 12, 126–127 (2012).

44. Dempster, E. R. & Lerner, I. M. Heritability of threshold characters. Genetics
35, 212–236 (1950).

45. Falconer, D. S. The inheritance of liability to certain diseases, estimated from
the incidence among relatives. Ann. Hum. Genet. 29, 51–76 (1965).

46. Davey Smith, G. Post-modern epidemiology: when methods meet meet.
Am. J. Epidemiol. 188, 1410–1419 (2019).

47. Davey Smith, G. Epigenesis for epidemiologists: does evo-devo have
implications for population health research and practice? Int. J. Epidemiol.
41, 236–247 (2012).

48. Wang, T. & Zheng, C. Q. Roles of cytokines in the pathogenesis of
inflammatory bowel disease. World Clin. J. Dig. 13, 72–75 (2005).

49. Wang, W., Sung, N., Gilman-Sachs, A. & Kwak-Kim, J. T helper (Th) cell
profiles in pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/
Th22/Th17 cells. Front. Immunol. 11, 2025 (2020).

50. Saito, S., Nakashima, A., Shima, T. & Ito, M. Th1/Th2/Th17 and regulatory
T-cell paradigm in pregnancy. Am. J. Reprod. Immunol. 63, 601–610 (2010).

51. Lim, K. J. H. et al. The role of T-helper cytokines in human reproduction.
Fertil. Steril. 73, 136–142 (2000).

52. Bakheet, S. A. et al. Resveratrol ameliorates dysregulation of Th1, Th2, Th17,
and T regulatory cell-related transcription factor signaling in a BTBR T + if/J
mouse model of autism. Mol. Neurobiol. 54, 5201–5212 (2017).

53. Abdallah, M. W. et al. Neonatal levels of cytokines and risk of autism
spectrum disorders: an exploratory register-based historic birth cohort study
utilizing the Danish Newborn Screening Biobank. J. Neuroimmunol. 252,
75–82 (2012).

54. Choi, G. B. et al. The maternal interleukin-17a pathway in mice promotes
autism-like phenotypes in offspring. Science 351, 933–939 (2016).

55. Fischbach, G. D. & Lord, C. The Simons Simplex Collection: a resource for
identification of autism genetic risk factors. Neurology 68, 192–195 (2010).

56. Daniels, A. M., Snyder, L. G., Eder, A. N. & Simon, A. R. SPARK: A US
cohort of 50,000 families to accelerate autism research NeuroView SPARK: a
US cohort of 50,000 families to accelerate autism research. Neuron 97,
488–493 (2018).

57. Kamran Ikram, M. et al. Four novel loci (19q13, 6q24, 12q24, and 5q14)
involve the microcirculation In vivo. PLoS Genet. 6, e1001184
(2010).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Methods
Throughout the text, the terms autism and autistic people/individuals are used, in line with recent evidence suggesting that these terms are preferred in the autistic community and are less stigmatizing18-20.

Study 1: Swedish cohort study
We used individual-level data from ‘Psychiatry Sweden’ to investigate whether parental IBD diagnosis is associated with autism diagnosis in children. ‘Psychiatry Sweden’ is a comprehensive national register linkage, with approval from the Stockholm regional ethical review committee (DNR 2010/1185-31.5, 2016/987-32). In line with the standards of all register-based research in Sweden and in keeping with the specific ethical approval for ‘Psychiatry Sweden’, informed patient consent was not required for the analysis of the anonymized data.

All children born in Sweden from 1 January 1987 to 31 December 2010 (N=2,837,045) were eligible index persons, with follow up to 31 December 2016. Exclusion criteria were: children born outside Sweden (n = 229,023), children not registered in the Medical Birth Register (n = 74,240), children resident in Sweden for under 5 years (n = 23,495), children of multiple pregnancy (n = 67,309), children who were adopted (n = 2,425), children who received a diagnosis of autism or ID who also had a documented genetic/metabolic condition known to cause neurodevelopmental disorders (for example, trisomies) (n = 7,873), or incomplete parental records (n = 45,435) (ref. 68). The study population included 2,324,227 children born to 1,282,494 mothers and 1,285,719 fathers (Extended Data Fig. 1).

The National Patient Register (NPR) includes inpatient care records beginning in 1973, outpatient physician visits in specialist care from 1997, outpatient psychiatric diagnoses (ICD-9 and ICD-10 codes) since 1973, and children and adolescent psychiatric care from 2011. Autism was identified in the National Patient Register (NPR) using ICD-9 and ICD-10 codes (Extended Data Fig. 9). Lifetime history of parental IBD, Crohn’s disease (Crohn’s) and ulcerative colitis (UC) were identified using ICD-9 and ICD-10 codes in the NPR (Extended Data Fig. 9). We used parental lifetime IBD diagnosis as the primary exposure. This approach was considered appropriate since data from outpatient specialist care were not originally included in the NPR and these were added starting in the late 1990s. Extended Data Fig. 9 illustrates the frequency of IBD diagnoses (for mothers and fathers of the study cohort) in NPR from 1987 to 2010.

Using STATA/MP17, we estimated the odds ratios and 95% CIs of the association of mother’s and father’s diagnosis of IBD (any IBD, Crohn’s, or UC) with autism in children using generalized estimating logistic models with robust standard errors accounting for clustering of multiple children born to the same parents.

Model 1 was unadjusted. Model 2 was adjusted for parental age at delivery9, migrant status5, education level, family income quintile at birth10, parents’ history of psychiatric diagnosis prior to the birth of the child, and child’s sex, birth year, and birth order (Supplementary Table S14 for collinearity diagnostics of covariates included in the models). Model 3 was additionally mutually adjusted for maternal and paternal IBD diagnoses to avoid bias from assortative mating19. Additionally, we investigated associations between any parental IBD diagnoses and autism in children with and without ID separately, since these groups may have distinct genetic and environmental risk factors15-16 and outcomes17-18. Due to the number of analyses run in the study, we applied a Bonferroni correction to account for multiple testing (0.05/42 = 0.0012). We compared the results of three sensitivity analyses with the results of the main analysis. First, we restricted parental IBD diagnoses to those recorded prior to the birth of the index person. Second, we adjusted Models 2 and 3 for parental lifetime autism diagnoses specifically, instead of the broad definition of parental psychiatric history used in the main analysis. Finally, we repeated the analyses without exclusion of the 7,873 children who had a documented genetic/metabolic condition assumed to be causing their neurodevelopmental disorder.

Study 2: LDSC
We used LDSC to estimate the genetic correlation between genetic liability to autism and IBD, Crohn’s, and UC
LDSC allows the estimation of the genetic correlation between polygenic traits using GWAS summary statistics by capitalizing on patterns of linkage disequilibrium among common genetic variants21. We used the latest available GWAS summary data on autism (Ngen = 18,381; Nmeta = 27,969) (ref. 70), IBD (Ngen = 25,042; Nmeta = 34,915) (ref. 71), Crohn’s (Ngen = 12,194; Nmeta = 28,072) (ref. 72), and UC (Ngen = 12,366; Nmeta = 33,609) (ref. 72). Detailed information on study samples and case definition can be found in the original publications.

We followed the suggested protocol for LDSC analyses (https://github.com/bulik/svs/blob/master/ldsc.md). Using the LDSC (LD score v.1.0.1 software in Python v.2.7.18, we estimated genetic correlations using pre-computed LD scores from the 1000 Genomes project European data73 (from: https://data.broadinstitute.org/alkesgroup/LDSCORE/eurwld_chr.tar.gz), with an unconstrained intercept term to account for any sample overlap and population stratification.

Ethics committee approval was not required for this analysis of publicly available GWAS summary statistics.

Study 3: Polygenic Risk Score analyses in the ALSPAC cohort
Discovery sample
Common genetic variants, corresponding alleles, effect sizes, and P values were extracted to calculate PRSs from the GWAS summary data of IBD11, UC12, and Crohn’s13 described above.

Target sample. ALSPAC is a UK prospective birth cohort study based in Bristol and surrounding areas, which recruited pregnant women with expected delivery dates from 1 April 1991 to 31 December 1992; 14,541 women were initially enrolled, with 14,062 children born, and 13,988 children alive at 1 year of age. Detailed information on the cohort is available elsewhere14-16. A fully searchable study data dictionary is available at: http://www.bristol.ac.uk/alspac/research-ethics/data-access-
Ethical information for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.

Genetic data. 10,015 ALSPAC mothers were genotyped on the Illumina Human660W quad genome wide single nucleotide polymorphism (SNP) genotyping platform at the Centre for Genomic Medicine at the University College London Genomics. Children were genotyped using Illumina GenomeStudio. A total of 9,912 ALSPAC children were genotyped on the Illumina HumanHap550 quad genotyping platforms by 23andme subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK, and the Laboratory Corporation of America, Burlington, NC, United States.

PLINK v1.07 was used for quality control filtering17. Specifically, individuals were excluded on the basis of the following filters: (1) gender mismatches; (2) undetermined X chromosome heterozygosity; (3) over 3% missingness (children); over 5% missingness (mothers); (4) evidence of cryptic relatedness (>10% of shared alleles identical by descent in children and >12.5% of shared alleles identical by descent in mothers); (5) non-European ancestry, assessed by multidimensional scaling analysis compared with HapMap 2 individuals. SNPs were excluded on the basis of the following filters: (1) minor allele frequency < 1%; (2) call rate < 95%, (3) Hardy–Weinberg equilibrium (HWE) P < 5.0 × 10⁻⁷. Maternal and offspring genotype data were combined and imputed using Impute v2.2.2 against 1000 Genomes reference panel (v1, phase 3, December 2013 release).

Using PLINK v1.07, we estimated the odds ratios and 95% CIs of the association between any parental IBD diagnoses and autism in children born to 1,282,494 mothers and 1,285,719 fathers (Extended Data Fig. 1).

Using STATA/MP17, we estimated the odds ratios and 95% CIs of the association between any parental IBD diagnoses and autism in children born to 1,282,494 mothers and 1,285,719 fathers (Extended Data Fig. 1).

Using STATA/MP17, we estimated the odds ratios and 95% CIs of the association between any parental IBD diagnoses and autism in children born to 1,282,494 mothers and 1,285,719 fathers (Extended Data Fig. 1).

We used LDSC to estimate the genetic correlation between genetic liability to autism and IBD and its subtypes, and vice versa. This threshold has been found to have sufficient predictive ability for IBD and its subtypes19. We could not directly assess the predictive power and optimal P-value threshold of the PRSs in our target sample, as there were fewer genotyped mothers and children with these measures.

Calculation of PRSs in ALSPAC and statistical analysis. PRSs were calculated using PLINK v1.07, applying the method described by the Psychiatric Genomics Consortium (PGC)9. SNPs with mismatching alleles between the discovery and target dataset were removed. The Major Histocompatibility Complex (MHC) region was removed (25–34 Mb), except for one SNP representing the strongest signal within the region. Using ALSPAC data as the reference panel, SNPs were clumped with an r² of 0.25 and a physical distance threshold of 500 kbp. The optimal P-value threshold for PRS is dependent on discovery and target sample sizes, as well as SNP inclusion parameters (for example, r²) (ref. 9, 10). For this reason, we calculated PRS for each participant across 13 P-value thresholds (P < 5.0 × 10⁻⁴ to P < 0.5), standardized by subtracting the mean and dividing by the standard deviation. We defined PRS corresponding to P-value threshold 0.05 as our primary exposure, based on a previous ALSPAC study22. This threshold has been found to have sufficient predictive ability for IBD and its subtypes23. We could not directly assess the predictive power and optimal P-value threshold of the PRSs in our target sample, as there were fewer UC (n = 12) and Crohn’s cases (n = 16).

After constructing PRSs for IBD, UC, and Crohn’s in mothers and children, we performed linear regressions using STATA/MP 15 to examine associations with the standardized autism factor mean score in childhood. Analyses were adjusted for child’s sex and the first ten principal components of the ALSPAC genotype data to avoid population stratification bias24.

Study 4: Two-sample MR
We performed two-sample MR to assess bidirectional causal links between genetic liability to autism and IBD and its subtypes, and vice versa.

MR can be implemented as an instrumental variable approach, utilizing common genetic variants as instruments for exposures of interest, allowing assessment of causal effects and their direction on outcomes. MR relies on the following assumptions: (1) the instruments must be a robust association between the common genetic variants and the exposure (that is, no horizontal pleiotropy, the phenomenon in which the genetic variant influences multiple phenotypes through biologically distinct pathways); (2) the variants should operate on the outcome entirely via the exposure; and (3) the variants should not be associated with any confounders of associations between exposure and outcome14. In this study, we applied two-sample MR, which relies on the robustness of the instruments for the exposure and the outcome were extracted from separate GWASs conducted in independent samples from the same underlying population14.
Genetic instruments. Genetic instruments were extracted from the overlapping set of SNPs between the autism\(^1\), IBD\(^2\), UC\(^3\), and Crohn's\(^4\) GWASs. This ensured that all selected genetic instruments would be present in the outcome GWAS.

GWAS summary data were restricted to a common set of SNPs and then clumped in PLINK 1.90 using the 1000 Genomes\(^5\) phase 3 European ancestry reference panel, and an\(^\text{r}^2 = 0.01\), within a 10,000 Kb window. Among the independent variants, instruments were defined using a genome-wide significance threshold of \(P < 5 \times 10^{-8}\). The only exception was autism, as only two independent and genome-wide significant variants were identified. We therefore relaxed the \(P\)-value threshold to \(5 \times 10^{-7}\) to improve statistical power, as used previously\(^6\).

Extended Data Fig. 7 illustrates the process of instrument definition, and Supplementary Table S8 contains information on the genetic instruments used.

Sensitivity analyses. We assessed the strength of the instruments by estimating the mean \(F\) statistic. As a rule of thumb, the IVW is unlikely to suffer from weak instrument bias if mean \(F > 10\) (ref. \(^7\)).

We assessed the consistency of the IVW causal effect estimates using sensitivity analyses, including MR Egger regression\(^8\), weighted median\(^9\), and weighted mode\(^10\) (Supplementary Table 20).

The autism GWAS used in our primary analyses included a proportion of autism cases with ID\(^2\). We tested the consistency of the causal effect estimates using GWAS summary data on a subsample of the iPSYCH cohort\(^11\) excluding all intellectual disability cases (\(N_{\text{ADHD}} = 11,203; N_{\text{ID}} = 22,555\)). Extended Data Fig. 8 visualizes the process of instrument definition, and Supplementary Tables S9, S17 and S18 contain details on the instruments used and the harmonized datasets.

Two-sample MR analyses were performed using the TwoSampleMR R package\(^12\) in R v.3.5.1. Ethics committee approval was not required for this analysis of GWAS summary statistics.

Reporting summary. Further information on research design is available in the Nature Research Reporting summary linked to this article.

Data availability

Swedish registry data: Individual-level data from ‘Psychiatry Sweden’ were used and under ethics approval from the Stockholm regional ethical review committee (DNR 2010:1185-31/5, 2016:987-32). Due to the sensitive nature of the data, data are not publicly available. Data must remain in the country, according to national laws and registry regulations. Access is restricted to projects approved by the Swedish ethical review authority (https://etikprövningsmyndigheten.se/) and in agreement with the register holders. See https://www.registerforskning.se/en/ for guidance on how to conduct Swedish register-based research. Since there is no central access point for public authority data in Sweden, this process may require coordination with multiple register holders (for example, Statistics Sweden, The National Board of Health and Welfare) and requires, in our experience, at least 1 year from the time of ethical approval, depending on workload for each register holder.

GWAS summary data: GWAS summary data for IBD, UC, Crohn’s, and autism used in the LDSC, PRS and MR analyses, are publicly available (IBD: http://ftp.ebi.ac.uk/pub/databases/gwas/summary_stats/GCT004001-GCT005000/GCT0041311/UC: http://ftp.ebi.ac.uk/pub/databases/gwas/summary_stats/GCT004001-GCT005000/GCT0041312/Crohn: http://ftp.ebi.ac.uk/pub/databases/gwas/summary_stats/GCT004001-GCT005000/GCT0041313/autism: https://www.med.ucn.dk/pgc/download-results/). Restrictions apply to the availability of the GWAS summary data for autism without IDs, in order to ensure that there is no conflict with ongoing projects, collaborations and iPSYCH’s data-sharing policies. Data can be accessed after correspondence with the iPSYCH: https://ipsych.dk/. Researchers will be asked to prepare a short application, briefly describing the proposed study, and responses will typically be within 2 weeks.

ALSPAC data: Ethical approval for the study was obtained from the ALSPAC Ethics Committee and the Local Research Ethics Committees. Individual-level data from the ALSPAC birth cohort are not publicly available for reasons of clinical confidentiality. Data can be accessed after application to the ALSPAC Executive Team who will respond within 10 working days. Application instructions and data use agreements are available at http://www.bristol.ac.uk/alspac/researchers/access/.

The minimum dataset for MR analyses is available in Supplementary Tables 8, 9, 15, 16, 17, and 18.

Code availability

Analyses were conducted using established protocols for each analytic approach used in the present study. Specifically, in the case of LDSC, the protocol described at: https://github.com/bulik/lsc/wiki/Heritability-and-Gene-Correlation-was used. In the case of PRS calculation, the approach described at: https://www.nature.com/articles/nature13595 was applied. Finally, for two-sample MR, the approach described at: https://mrcieu.github.io/TwoSampleMR/articles/introduction.html was used.

References

58. Kenny, L. et al. Which terms should be used to describe autism? Perspectives from the UK autism community. Autism 20, 442–462 (2016).

59. Bottema-Butel, K., Kapp, S. K., Lester, J. N., Sasson, N. J. & B. Avoiding ableist language: Suggestions for autism researchers. Autism in Adolescence 3, 18–29 (2021).

60. Chen, S., Zhao, S., Dalman, C., Karlsson, H. & Gardner, N. Association of maternal diabetes with neurodevelopmental disorders: autism spectrum disorders, attention-deficit/hyperactivity disorder and intellectual disability. Int. J. Epidemiol. 50, 459–474 (2021).

61. Sanders, S. J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. Neuron 87, 1215–1233 (2015).

62. Rai, D. et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. Brit. Med. J. 346, D659 (2013).

63. Rai, D. et al. Antidepressants during pregnancy and autism in offspring: population based cohort study. Obstet. Gynecol. Surv. 72, 689–692 (2017).

64. Amiet, C. et al. Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol. Psychiatry 64, 577–582 (2008).

65. Rai, D. et al. Association between autism spectrum disorders with or without intellectual disability and depression in young adulthood. JAMA Netw. JAMA Netw. Open 1, e181465–e181465 (2018).

66. Altshuler, D. M. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).

67. Stergiakouli, E. et al. Genome-wide association study of height-adjusted BMI in childhood identifies variant feature in ADCY3. Obesity 22, 2252–2259 (2014).

68. Sun, M. et al. Biological insights from 108 schizophrenia-associated genetic loci (METHODS). Nature 530, 171–176 (2016).

69. Dubridge, F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 9, e1003348 (2013).

70. Jones, H. J. et al. Association of Genetic Risk for Rheumatoid Arthritis with Cognitive and Psychiatric Phenotypes Across Childhood and Adolescence. JAMA Netw. Open 2, e196118–e196118 (2019).

71. Haycock, P. C. et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am. J. Clin. Nutr. 103, 965–978 (2016).

72. Gao, X. et al. The bidirectional causal relationships of insomnia with five major psychiatric disorders: a Mendelian randomization study. Eur. Psychiatry 60, 79–85 (2019).

73. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015).

74. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304–314 (2016).

75. Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol. 46, 1985–1998 (2017).

76. Pedersen, C. B. et al. The iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders. Mol. Psychiatry 23, 6–14 (2018).

77. Hemani, G. et al. The MR-base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018).

78. Chen, S., Zhao, S., Dalman, C., Karlsson, H. & Gardner, N. Association of maternal diabetes with neurodevelopmental disorders: autism spectrum disorders, attention-deficit/hyperactivity disorder and intellectual disability. Int. J. Epidemiol. 50, 459–474 (2020).

Acknowledgements

The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/5, MC_UU_00011/6, MC_UU_00011/7, P.J. H., E.J. S., G.M.K., H.J., G.D.S., G.D.S., H.J., D.R., S.S., and S.Z. are supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. G. Dardani acknowledges the support of Wellcome Trust (215379/Z/19/Z). G.M.K. acknowledges funding support from the Wellcome Trust (201486/Z/16/Z), and the MRC UK (MR/W014161/1 and MR/P037675/1). The iPSYCH team was supported by grants from the
Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIMH (1U01MH109514-01), and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSCYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Center for Integrative Sequencing, iSEQ, Aarhus University, Denmark. R.G. acknowledges funding support from the Swedish Research Council (VR2017-02900). A.H. was supported by grants from the southeastern Norway Regional Health Authority (2020022, 2018059) and the Research Council of Norway (274611, 288083). H.K. is supported by grants from the Swedish Research Council (2018-02907) and Hjärnfonden (FO2020-0019). C. Dalman acknowledges funding from the Swedish Research Council (523-2010-1052) to support the Psychiatry Sweden register linkage and for further support of studies of the role of the early life immune system in autism (2021-01306). The UK Medical Research Council and Wellcome (Grant ref: 217085/Z/19/Z) and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses.

Author contributions
Research idea; C. Dardani; Study design and supervision; C. Dardani, R.G., DR; Data analysis: A.S., C. Dardani, R.G.; Interpretation of results: A.S., C. Dardani, PP, A.H., E.S., J.G., G.M.K., S.S., S.Z., H.J., G.D.S., C. Dalman, H.K., R.G., D.R.; Drafting of manuscript: A.S., C. Dardani, R.G., D.R.; Critical comments and editing of manuscript drafts: A.S., C. Dardani, P.P., A.H., E.S., J.G., G.M.K., S.S., S.Z., H.J., G.D.S., C. Dalman, H.K., R.G., D.R.; Approval of final submitted manuscript: A.S., C. Dardani, PP, A.H., E.S., J.G., G.M.K., S.S., S.Z., H.J., G.D.S., C. Dalman, H.K., R.G., D.R.

Competing interests
The authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41591-022-01845-9.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41591-022-01845-9.
Correspondence and requests for materials should be addressed to Christina Dardani.

Peer review information Nature Medicine thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling editor: Anna Maria Ranzoni, in collaboration with the Nature Medicine team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Study sample derivation for the Swedish cohort study. **a,** Children born before 1987 were excluded from the study population. **b,** Individuals were excluded stepwise with the criteria aligned to a previous study (reference 78). **c,** Individuals without information from the MBR were excluded. **d,** Children with diagnoses of autism or IDs and genetic or metabolic conditions documented in the MBR that were known to cause neurodevelopmental disorders (NDDs), as the NDDs may be attributable to the condition. **e,** Those whose biological fathers were unknown were excluded. **f,** Those whose biological mothers or fathers lacked data on place of birth, age at delivery, education level, psychiatric history, or family income quintile were excluded.
Extended Data Fig. 2 | Prevalence and overlap in diagnoses among the mothers included in the present study. Overall prevalences of Crohn’s, UC, and other IBD diagnoses are shown in terms of mothers diagnosed (j) as well as children born to those mothers and followed up for autism in Study 1 (index persons, i). Overlap in the diagnoses is only shown for index persons included in the study, to align with values in Table 2 in the main text, though the extent of overlap is virtually identical if mothers or index persons are displayed. For example, of the 7,000 mothers diagnosed with Crohn’s, 1,984 (28.4%) were also diagnosed with colitis, and the analogous proportion of children is 28.0% (3,466/12,390).
Extended Data Fig. 3 | Prevalence and overlap in diagnoses among the fathers included in the present study. Overall prevalences of Crohn’s, UC, and other IBD diagnoses are shown in terms of fathers diagnosed (j) as well as children born to those mothers and followed up for autism in Study 1 (index persons, i). Overlap in the diagnoses is only shown for index persons included in the study, to align with values in Table 2 in the main text, though the extent of overlap is virtually identical if fathers or index persons are displayed. For example, of the 6,244 fathers diagnosed with Crohn’s, 1,925 (30.8%) were also diagnosed with colitis, and the analogous proportion of children is 30.3% (3,414/11,274).
Extended Data Fig. 4 | Study sample derivation and characteristics for the PRS analyses in ALSPAC. *Although initial ALSPAC recruitment resulted in 13,988 children who were alive at 1 year of age, when the children were approximately 7 years old, the initial sample was bolstered with eligible children who did not join the study initially. 913 children were additionally enrolled during three phases of recruitment. This resulted in 14,901 children alive at 1 year of age. Detailed information can be found at references 24–26,64–66. Details on QC process can be found in Methods. **Consent for biological samples has been collected in accordance with the Human Tissue Act (2004).
Extended Data Fig. 5 | See next page for caption.
Extended Data Fig. 5 | Associations between maternal polygenic risk score for IBD, UC, Crohn’s, and autism factor mean score in the children, at 13 P-value thresholds for PRS generation. \( n = 7,348 \) mother–child pairs. Data are presented as beta coefficients and 95% CIs. Calculated by linear regression of the mothers’ PRS for IBD, UC, or Crohn’s on the standardized autism factor mean score in the children, adjusted for child’s sex and the first ten principal components of the ALSPAC genotype data.
Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Associations between children’s polygenic risk score for IBD, UC, Crohn’s, and autism factor mean score, at 13 P-value thresholds for PRS generation. \( n = 7,503 \) children. Data are presented as beta coefficients and 95% CIs. Calculated by linear regression of the children’s PRS for IBD, UC, or Crohn’s on the standardized autism factor mean score in the children, adjusted for child’s sex and the first ten principal components of the ALSPAC genotype data.
Extended Data Fig. 7 | Genetic instrument extraction process for the MR analyses investigating the causal links between genetic liability to autism and IBD, UC, and Crohn’s. Between phenotype pairs, GWAS summary data were restricted to a common set of SNPs and then clumped in PLINK 1.90 using the 1000 Genomes phase 3 European ancestry reference panel, and an $r^2 = 0.01$, within a 10,000 Kb window. Among the independent variants, instruments were defined using a genome-wide significance threshold of $P \leq 5 \times 10^{-8}$. The only exception was autism, as only two independent and genome-wide significant variants were identified. We therefore relaxed the $P$-value threshold to $5 \times 10^{-7}$ to improve statistical power, as used previously.)
Extended Data Fig. 8 | Genetic instrument extraction process for the MR analyses investigating the causal links between genetic liability to autism without ID (iPSYCH subsample) and IBD, UC, and Crohn’s. Between phenotype pairs, GWAS summary data were restricted to a common set of SNPs and then clumped in PLINK 1.90 using the 1000 Genomes phase 3 European ancestry reference panel, and an $r^2 = 0.01$, within a 10,000 Kb window. Among the independent variants, instruments were defined using a genome-wide significance threshold of $P \leq 5 \times 10^{-8}$. The only exception was autism, as only two independent and genome-wide significant variants were identified. We therefore relaxed the $P$-value threshold to $5 \times 10^{-7}$ to improve statistical power, as used previously72.
Extended Data Fig. 9 | Ascertainment of outcomes and exposures from the National Patient Register (NPR). a, Diagnostic codes for ascertainment of outcomes and exposures. b, Frequency of IBD diagnoses, by year, in NPR for study cohort mothers from 1987 to 2010. c, Frequency of IBD diagnoses, by year, in NPR for study cohort fathers from 1987 to 2010. ICD-9: International Classification of Diseases – ninth edition; ICD-10: International Classification of Diseases – tenth edition.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- n/a Confirmed
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  *Give P values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection: No software used for data collection.

Data analysis:

- Data analysis
  - Swedish registry data: STATA/17MP
  - LD score regression: LDSC(LD Score) v1.0.1 software in Python 2.7.18
  - Polygenic risk score estimation: PLINK version 1.9
  - Polygenic risk score analyses: STAT/15MP
  - Two-sample Mendelian randomization: TwoSampleMR R package in R version 3.5.1

Code availability statement: Analyses were conducted using established protocols for each analytic approach used in the present study. Specifically in the case of LD score regression, the protocol described at: https://github.com/bulik/lodc/wiki/Heritability-and-Genetic Correlation, was used. In the case of polygenic risk score calculation, the approach described at: https://www.nature.com/articles/ nature13595, was applied. Finally, for two-sample Mendelian randomization, the approach described at: https://mcieu.github.io/ TwoSampleMR/articles/introduction.html, was applied.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Github). See the Nature Research guidelines for submitting code & software for further information.
Data

Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Swedish registry data: Individual-level data from ‘Psychiatry Sweden’ were used and under ethics approval from the Stockholm regional ethical review committee [DNR 2010/1185-31/5, 2016/587-32]. Due to the sensitive nature of the data, data are not publicly available. Data must remain in the country, according to national laws and registry regulations. Access restrictions is limited to projects approved by the Swedish ethical review authority (https://etikknovingsmyndigheten.se/) and in agreement with the register holders. See https://www.registerforsknings.se/en/ for guidance on how to conduct Swedish register-based research. Since there is no central access point for public authority data in Sweden, this process may require coordination with multiple register holders [e.g., Statistics Sweden, The National Board of Health and Welfare] and requires, in our experience, at least one year from the time of ethical approval, depending on workload for each register holder.

GWAS summary data: GWAS summary data for IBD, ulcerative colitis, Crohn’s disease and autism used in the LD score regression, polygenic risk score and Mendelian randomization analyses, are publicly available (IBD: http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST004001-GCST005000/GCST004131/; UC: http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST004001-GCST005000/GCST004132/; Crohn’s: http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST004001-GCST005000/GCST004133/; Autism: https://www.med.unc.edu/pgc/download-results/). Restrictions apply to the availability of the GWAS summary data for autism without intellectual disabilities, in order to ensure that there is no conflict with ongoing projects, collaborations and iPSYCH’s data sharing policies. Data can accessed after correspondence with the iPSYCH: https://ipsych.dk/). Researchers will be asked to prepare a short application briefly describing the proposed study and responses will typically be within 2 weeks.
1000 Genomes project European data used in LD score regression is publicly available (from: https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_wid_chr.tar.gz).

ALSPAC data: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Individual-level data from the ALSPAC birth cohort are not publicly available for reasons of clinical confidentiality. Data can be accessed after application to the ALSPAC Executive Team who will respond within 10 working days. Application instructions and data use agreements are available at http://www.bristol.ac.uk/alspac/researchers/access/.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size
The Swedish registry cohort study was conducted in a sample of 3,234,227 offspring born to 1,282,494 mothers and 1,285,719 fathers. Post hoc power calculations suggested that we had over 80% power to detect an odds ratio of 1.1. For the LD score, polygenic risk score estimation and two-sample Mendelian randomization studies we used the latest publicly available summary data, to increase the power of the analyses. Specifically: autism (Ncases= 18,381; Ncontrols= 27,969), autism excluding intellectual disabilities cases (Ncases= 11,203; Ncontrols= 22,555), IBD (Ncases= 25,042; Ncontrols= 34,915), Crohn’s (Ncases= 12,194; Ncontrols= 28,072) and UC (Ncases= 12,366; Ncontrols= 33,609).

For the polygenic risk score analyses in the ALSPAC birth cohort, we used as an outcome variable the autism factor mean score, a broad autism phenotype measure available in ~13,000 children in the cohort. This ensured we would have the largest sample size possible for these analyses in ALSPAC.

Data exclusions
Case definition and participant exclusion criteria for the Swedish registry cohort study are illustrated in Figure S1 of the supplementary material. In summary, exclusion criteria were: children born outside Sweden (n=292,023), not registered in the Medical Birth Register (n=74,240), resident in Sweden for <5 years (n=23,495), multiple pregnancy (n=67,309), adopted (n=2,425), known genetic/metabolic causes of neurodevelopmental conditions (e.g. trisomies) (n=7,873) or incomplete parental records (n=45,453).

In the case of LD score regression, polygenic risk score analyses and two-sample Mendelian randomization, all available data were used after applying quality control procedures suggested from the developers of the approaches (https://github.com/bulik/dsc/wiki/Heritability-and-Gene-EQCorrelation; https://www.nature.com/articles/nature13595; https://mcorie.github.io/1TwoSampleMR/Articles/introduction.html). Quality control procedures for the ALSPAC genotype data can be found in Supplementary Methods S2 of the supplement and in Stergakouli E, Gaillard R, Tavaré JM, et al. Genome-wide association study of height-adjusted BMI in childhood identifies functional variant in ADCCYS. Obesity (Silver Spring). 2014;22(10):2252-2259.

In LD-score regression quality control steps, single nucleotide polymorphisms (SNPs) are excluded if they are not present in the 1000 Genomes European LD-reference panel, they have missing values, imputation INFO scores < 0.9, minor allele frequency <0.01, have out-of-bounds p-values, are strand-ambiguous or duplicates.
In PRS quality control Individuals were excluded on the basis of the following filters:
1. gender mismatches,
2. undetermined X chromosome heterozygosity,
3. over 3% missingness (children), over 5% missingness (mothers),
4. evidence of crypted relatedness; >10% of shared alleles identical by descent in children and >12.5% of shared alleles identical by descent in mothers,
5. non-European ancestry, assessed by multidimensional scaling analysis compared to HapMap 2 individuals.

SNPs were excluded on the basis of the following filters:
1. minor allele frequency <1%,
2. call rate < 95%,
3. Hardy-Weinberg equilibrium (HWE) p<5e-07.

Also SNPs with mismatching alleles between the discovery and target dataset were removed. The MHC region was removed (25 Mb – 34 Mb), except for one SNP representing the strongest signal within the region.

For Mendelian randomization, SNPs were excluded if they were not present in both the exposure and outcome GWAS. During the harmonization step, SNPs were excluded if they were paipdromic (i.e. the alleles on the forward strand are the same as the reverse strand) as this prevented correct harmonization.

Replication
We used four complementary designs. We found evidence of associations between maternal diagnosis and polygenic risk for IBD subtypes and offspring autism. This was further supported by two-sample Mendelian randomization analyses suggesting a causal effect of genetic liability to ulcerative colitis on autism. Despite triangulating our findings, replication in other international cohorts is necessary to build on the findings and their possible explanations. No direct replication of each individual analysis was done.

Randomization
In the Swedish registry cohort study we controlled for covariates including: paternal age at delivery, migrant status, education level, family income quintile at birth, parents' history of psychiatric diagnosis prior to the birth of the child and offspring sex, birth year and birth order. We additionally mutually adjusted for maternal and paternal IBD diagnoses to avoid bias from assortative mating.

In the ALSPAC polygenic risk score analysis we controlled for child's sex and the first 10 principal components of the ALSPAC genotype data to avoid population stratification bias. Finally, Mendelian randomization has been compared to a natural randomized controlled trial, as genetic variants used as instruments are allocated randomly during meiosis. This is similar to blinding at allocation.

Blinding
Blinding of the samples was not applied and not relevant as no interventions were conducted.

Report for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| ☒ | Antibodies            |
| ☒ | Eukaryotic cell lines |
| ☒ | Palaeontology and archaeology |
| ☒ | Animals and other organisms |
| ☒ | Human research participants |
| ☒ | Clinical data         |
| ☒ | Dual use research of concern |

Methods

| n/a | Involved in the study |
|-----|-----------------------|
| ☒ | ChiP-seq              |
| ☒ | Flow cytometry        |
| ☒ | MRI-based neuroimaging |